Sanofi and Sobi, along with the World Federation of Hemophilia (WFH) and WFH USA recently announced as extension of the two companies’ support of the WFH Humanitarian Aid Program. The enhanced support includes an additional donation of up to 500 million IUs of factor therapy product for humanitarian use – this fulfills a 2014 pledge to donate up to 1 billion IUs over a ten-year period.
According to a Sanofi press release, since the initial 2014 pledge more than 450 million IUs have been donated and more than 17,200 people with hemophilia have been treated with factor donated by the two companies between 2015 and 2019. Additionally, the companies will continue to provide financial support for initiatives such as treatment, access and education programs for a period up to five years
“Through this partnership with Sanofi and Sobi, our Founding Visionary Contributors, we have been able to significantly expand the reach of the WFH Humanitarian Aid Program, which is leading to a paradigm shift in the management of hemophilia in areas with limited or no access to treatment and care,” said Alain Baumann, Chief Executive Officer, World Federation of Hemophilia. “With their continued support, we are confident that people with hemophilia in these countries will continue to receive much needed treatment that is both predictable and sustainable – the foundation of the WFH Humanitarian Aid Program. Our vision at WFH is treatment for all.”
Source: Sanofi press release dated June 14, 2020